Spruce Biosciences appoints Javier Szwarcberg as CEO, promotes Samir Gharib to President

SPRUCE BIOSCIENCES, INC.

Javier Szwarcberg, M.D., MPH, appointed CEO and director effective Jan 3, 2022; succeeds interim CEO Michael Grey, who remains Executive Chairman.
Samir Gharib, MBA, promoted to President while continuing as CFO; salary increased to $430,000 with target bonus of 45%.
Szwarcberg receives options to purchase 1,000,000 shares at $4.59; 750k time-vested over 4 yrs, 250k performance-vested on CAHmelia-204 trial milestones.
Preliminary cash, cash equivalents and investments estimated at $121.4M as of Dec 31, 2021 (unaudited).

item 2.02 item 8.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Michael Grey

Interim Chief Executive Officer

SPRB · SPRUCE BIOSCIENCES, INC.

Effective: 2022-01-03
Successor: Javier Szwarcberg
Filed: January 5, 2022, 6:59 PM ET

Dr. Szwarcberg will succeed Michael Grey, who had served as the Company’s Interim Chief Executive Officer since November 15, 2021, and who will continue to hold his position as Executive Chairman of the Board.

Appointed

Javier Szwarcberg

Chief Executive Officer

SPRB · SPRUCE BIOSCIENCES, INC.

Effective: 2022-01-03
Filed: January 5, 2022, 6:59 PM ET

appointed Javier Szwarcberg, M.D., MPH, as the Company’s Chief Executive Officer, effective January 3, 2022

Appointed

Javier Szwarcberg

Class III director

SPRB · SPRUCE BIOSCIENCES, INC.

Effective: 2022-01-03
Filed: January 5, 2022, 6:59 PM ET

the Board also appointed Dr. Szwarcberg as a member of the Board effective as of the Start Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Michael Grey changed role as Interim Chief Executive Officer at SPRUCE BIOSCIENCES, INC..

Role: Interim Chief Executive Officer

Exact text from the filing

Dr. Szwarcberg will succeed Michael Grey, who had served as the Company’s Interim Chief Executive Officer since November 15, 2021, and who will continue to hold his position as Executive Chairman of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Javier Szwarcberg was appointed as Chief Executive Officer at SPRUCE BIOSCIENCES, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

appointed Javier Szwarcberg, M.D., MPH, as the Company’s Chief Executive Officer, effective January 3, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Javier Szwarcberg was appointed as Class III director at SPRUCE BIOSCIENCES, INC..

Action: appointed
Role: Class III director

Exact text from the filing

the Board also appointed Dr. Szwarcberg as a member of the Board effective as of the Start Date.

View on SEC.gov

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001564590-22-000432

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.